{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:12:47Z","timestamp":1772212367065,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Tadalafil, a once\u2010daily phosphodiesterase type 5 inhibitor (<jats:styled-content style=\"fixed-case\">PDE<\/jats:styled-content>\u20105I), offers clinicians an alternative to sildenafil, a 3\u2010times\u2010daily (t.i.d.) <jats:styled-content style=\"fixed-case\">PDE<\/jats:styled-content>\u20105I for treatment of pulmonary arterial hypertension (<jats:styled-content style=\"fixed-case\">PAH<\/jats:styled-content>). However, there are limited data describing the risks and benefits or recommended methodology of switching patients from sildenafil to tadalafil.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Chart reviews were conducted on all <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>orld <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ealth <jats:styled-content style=\"fixed-case\">O<\/jats:styled-content>rganization group 1 patients on sildenafil for \u22653\u00a0months who transitioned to tadalafil with documented clinic visits and 6\u2010min walk tests on both drugs. Most patients were transitioned by discontinuing sildenafil after the evening dose and initiating tadalafil 40\u00a0mg\/day the next day. Data collected included demographics, <jats:styled-content style=\"fixed-case\">PAH<\/jats:styled-content> etiology, diagnostic hemodynamics, 6\u2010min walk distance (6<jats:styled-content style=\"fixed-case\">MWD<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">PDE<\/jats:styled-content>\u20105I side effects, and concomitant medications. Data on <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010type natriuretic peptide (<jats:styled-content style=\"fixed-case\">BNP<\/jats:styled-content>) levels were available for most patients also receiving endothelin receptor antagonists (<jats:styled-content style=\"fixed-case\">ERA<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Medical records from 98 patients were evaluated. Most patients (92%) were on sildenafil for &gt;1\u00a0year, and 78% were receiving sildenafil 80\u2013100\u00a0mg t.i.d. Ninety\u2010seven percent of patients (95\/98) were successfully transitioned and maintained on 40\u00a0mg\/day. With a mean duration on tadalafil therapy of 243\u00a0\u00b1\u00a0127\u00a0days at the time of analysis, 6<jats:styled-content style=\"fixed-case\">MWD<\/jats:styled-content> was unchanged. Patient\u2010reported adverse events included headache (4%) and heartburn (2%). There was minimal change in <jats:styled-content style=\"fixed-case\">BNP<\/jats:styled-content> levels in the subset of patients receiving an <jats:styled-content style=\"fixed-case\">ERA<\/jats:styled-content> concomitantly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Transition from sildenafil to tadalafil 40\u00a0mg\/day appears feasible without clinical deterioration or intolerable side effects. This study provides guidance to physicians considering transition from sildenafil to tadalafil for selecting patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12038","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T12:01:43Z","timestamp":1373457703000},"page":"274-279","source":"Crossref","is-referenced-by-count":13,"title":["Safety, Tolerability, and Efficacy of Overnight Switching From Sildenafil to Tadalafil in Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1111","volume":"31","author":[{"given":"Shelley","family":"Shapiro","sequence":"first","affiliation":[{"name":"Greater Los Angeles Veterans Affairs Healthcare System Los Angeles CA USA"},{"name":"David Geffen School of Medicine at the University of California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenna","family":"Traiger","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at the University of California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Hill","sequence":"additional","affiliation":[{"name":"Greater Los Angeles Veterans Affairs Healthcare System Los Angeles CA USA"},{"name":"David Geffen School of Medicine at the University of California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Zhang","sequence":"additional","affiliation":[{"name":"United Therapeutics Corporation Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee K.","family":"Doran","sequence":"additional","affiliation":[{"name":"United Therapeutics Corporation Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035488"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192230"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2006.12.002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/004982599238687"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01049.x"},{"key":"e_1_2_9_7_1","volume-title":"Pfizer Labs, Division of Pfizer Inc.","author":"REVATIO Lab\u20100335\u20104.0","year":"2009"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02553.x"},{"key":"e_1_2_9_10_1","volume-title":"Adcirca","author":"Eli Lilly and Company","year":"2009"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-012-9408-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.756399"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0275"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12038","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:35:55Z","timestamp":1696232155000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/1755-5922.12038"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12038","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}